


## PHARMACEUTICAL 2019

APTINYX

## Aptinyx Inc. Rank 40 of 363





RealRate

## PHARMACEUTICAL 2019



## Aptinyx Inc. Rank 40 of 363

The relative strengths and weaknesses of Aptinyx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aptinyx Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Aptinyx Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 251%, being 215% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	153,251
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,885
Liabilities, Non-Current	418
Other Assets	673
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,607
Other Revenues	6,574
Property and Equipment	1,690
Research and Development	48,788
Selling, General and Administrative Expense	12,674

Output Variable	Value in 1000 USD
Assets	155,614
Liabilities	6,303
Expenses	61,462
Revenues	6,574
Stockholders Equity	149,311
Net Income	-53,281
Comprehensive Net Income	-53,281
Economic Capital Ratio	251%

